RESUMO
The pharmacokinetics of vigabatrin were investigated after single and multiple oral doses in two groups of 24 healthy male volunteers. Vigabatrin was well tolerated by the volunteers; headache was the most frequently reported adverse event. There were no clinically remarkable changes in serum chemistry, urinalysis, or hematology attributable to vigabatrin. For the single-dose study, a stepwise linear contrast method was used to assess dose proportionality. The results showed that vigabatrin exhibited dose linear pharmacokinetics after single oral doses ranging from 0.5 to 4.0 g. Slight changes in the terminal phase half-life and renal clearance were evident in the higher dosage groups. These changes with increasing dose of vigabatrin were relatively minor and not considered to be clinically important. Evaluation of the multiple-dose pharmacokinetics indicated that vigabatrin exhibited dose linearity over the range of 0.5 to 2.0 g administered every 12 hours. The terminal phase half-life and renal clearance of vigabatrin during multiple dosing were consistent with that after single doses. During multiple dosing, steady-state concentrations of vigabatrin were reached on the second day of dosing, and drug accumulation was minimal.
Assuntos
Aminocaproatos/farmacocinética , Anticonvulsivantes/farmacocinética , Administração Oral , Adolescente , Adulto , Aminocaproatos/administração & dosagem , Aminocaproatos/efeitos adversos , Anticonvulsivantes/administração & dosagem , Anticonvulsivantes/efeitos adversos , Esquema de Medicação , Meia-Vida , Humanos , Masculino , Taxa de Depuração Metabólica , VigabatrinaRESUMO
Administration of terfenadine (Seldane) immediately after a high fat breakfast slightly affects the rate but not the extent of absorption relative to fasting administration. Mean peak levels of the active metabolite were increased by 13 per cent but delayed by 0.9 h while AUC was virtually the same as when terfenadine was administered while fasting. Changes in rate of absorption may be due to delayed gastric emptying and more rapid terfenadine solubilization. In any case, these rate differences are unlikely to be clinically important in the absence of differences in extent of absorption.
Assuntos
Gorduras na Dieta/administração & dosagem , Jejum/metabolismo , Terfenadina/farmacocinética , Adulto , Disponibilidade Biológica , Humanos , Absorção Intestinal/efeitos dos fármacos , Masculino , Terfenadina/sangue , Terfenadina/metabolismoRESUMO
Teicoplanin pharmacokinetics were investigated upon multiple dose intravenous administration of 6 and 12 mg kg-1 in 10 normal, healthy, male volunteers, using a two-period, randomized, crossover design; six subjects completed both periods. On day 1, 6 or 12 mg kg-1 was administered every 12 h as a 30-min constant rate intravenous infusion (two doses). Starting on day 2, the same dose (6 or 12 mg kg-1) was administered every 24 h for an additional 13 days. Blood and urine samples were collected over 21 days. Serum and urine were analyzed using a microbiological assay. Following a minimum of 3 weeks after completion of the first period, subjects were crossed over to the other dose. Following multiple dose intravenous administration of 6 and 12 mg kg-1, median pharmacokinetic parameters included: steady-state volume of distribution of 1.4 and 1.2 l kg-1; total clearance of 12.2 and 14.0 ml h-1 kg-1; renal clearance of 11.1 and 10.3 ml h-1 kg-1; and terminal disposition half-life of 159 and 155 h, respectively. No statistically significant dose-related difference was observed. In addition, a cross-study comparison further supports dose proportionality of teicoplanin upon multiple dose intravenous administration of 3 to 12 mg kg-1.
Assuntos
Antibacterianos/farmacocinética , Adulto , Antibacterianos/administração & dosagem , Antibacterianos/sangue , Esquema de Medicação , Glicopeptídeos/administração & dosagem , Glicopeptídeos/sangue , Glicopeptídeos/farmacocinética , Humanos , Injeções Intravenosas , Masculino , Distribuição Aleatória , TeicoplaninaRESUMO
The pharmacokinetics of the terfenadine active metabolite, metabolite I, was examined in ten healthy elderly adults and ten younger adults after single-dose oral administration of 120-mg terfenadine. All subjects successfully completed the study without reporting sedation or other adverse events. Absorption was rapid in both the young and elderly. The mean Cmax was the same for both groups, 501 ng/mL, and occurred at 2.3 hours in the young subjects and 2.5 hours in elderly subjects. However, the apparent clearance was reduced by about 25% in the elderly. After correcting clearance for bodyweight, this difference was not statistically significant.
Assuntos
Terfenadina/farmacocinética , Administração Oral , Adulto , Idoso , Peso Corporal , Humanos , Absorção Intestinal , Masculino , Taxa de Depuração Metabólica , Terfenadina/administração & dosagem , Terfenadina/efeitos adversos , Terfenadina/metabolismo , Fatores de TempoRESUMO
Teicoplanin pharmacokinetics were evaluated after multiple-dose intravenous administration to healthy male volunteers by using a randomized, double-blind, parallel design. Doses of 3, 12, or 30 mg of teicoplanin per kg of body weight were administered every 24 h for 14 days as 60-min constant-rate intravenous infusions. Blood and urine samples were collected over 21 days and analyzed by a microbiological assay. Twenty-three subjects were included in the pharmacokinetic analysis. The median pharmacokinetic parameters upon multiple-dose intravenous administration of 3, 12, and 30 mg/kg included steady-state volumes of distribution of 0.94, 0.77, and 0.68 liter/kg; total clearances of 11.9, 12.0, and 13.2 ml/h/kg; and terminal disposition half-lives of 143, 166, and 96 h, respectively. Renal clearance accounted for approximately 95% of total clearance. No dose-related differences existed for teicoplanin total or renal clearance. The steady-state volume of distribution decreased significantly with increasing doses. As a result of the decrease in the volume of distribution, the terminal disposition half-life at 30 mg/kg was significantly decreased. However, the decreases in the volume of distribution and terminal disposition half-life are of limited clinical importance, since steady-state trough concentrations in serum increase in proportion to dose. Combined results of all multiple-dose studies with similar durations of sample collection indicate no dose-related differences for any pharmacokinetic parameters from 3 to 12 mg/kg. As observed in the present study, no dose-related differences exist for teicoplanin total and renal clearances from 3 to 30 mg/kg. However, at 30 mg/kg, a significant decrease in the steady-state volume of distribution is observed. As a consequence of the reduction in the volume of distribution at 30 mg/kg with no change in clearance, the terminal disposition half-life is decreased.
Assuntos
Antibacterianos/farmacocinética , Adulto , Antibacterianos/administração & dosagem , Antibacterianos/sangue , Método Duplo-Cego , Glicopeptídeos/administração & dosagem , Glicopeptídeos/sangue , Glicopeptídeos/farmacocinética , Meia-Vida , Humanos , Infusões Intravenosas , Masculino , Taxa de Depuração Metabólica , Distribuição Aleatória , TeicoplaninaRESUMO
Pharmacokinetics, bioavailability, and local tolerance (at the site of intramuscular administration) of a new formulation of teicoplanin (400 mg/3 mL) were investigated in 24 normal, healthy, male volunteers. A single dose of 6 mg/kg was administered intravenously and intramuscularly using a randomized crossover design. Volunteers and investigator were blinded as to the route of administration; placebo was administered by the other route. Blood and urine samples were collected for 21 days and were analyzed for microbiological activity. The median (range) pharmacokinetic parameters of teicoplanin following single-dose iv administration were as follows: steady-state volume of distribution of 1.6 (1.2-2.8) L/kg; total clearance of 10.2 (8.6-15.1) mL/h/kg; renal clearance of 10.0 (7.9-13.8) mL/h/kg; and terminal disposition half-life of 168 (111-278) h. Following single-dose im administration, significantly more subjects complained of pain following administration of teicoplanin (58%) compared with placebo (4%). Teicoplanin was completely absorbed with a median (range) peak serum concentration of 12.3 (6.6-37.5) micrograms/mL occurring at a median (range) time of 4.1 (0.7-6.1) h. Since the 90% confidence interval for the ratio of areas under the serum concentration-time curve falls within the range of 80 to 120%, the extent of systemic absorption of teicoplanin following im administration is equivalent to that following iv administration.
Assuntos
Antibacterianos/farmacocinética , Adulto , Disponibilidade Biológica , Método Duplo-Cego , Glicopeptídeos/farmacocinética , Humanos , Infusões Intravenosas , Injeções Intramusculares , Masculino , Pessoa de Meia-Idade , TeicoplaninaRESUMO
A prospective study of 315 cases of cardiac failure admitted to the General Hospital at Katsina, in the northern savanna region of Nigeria, is presented and the pattern emerged is compared with that of the southern forest region of the country. Although the diseases causing cardiac failure were similar in these two areas, their incidence and pattern showed wide variations. Cardiomyopathies were the commonest cause (47%) of cardiac failure in the northern savanna, congestive cardiomyopathy being the predominant type (31%). Endomyocardial fibrosis (EMF) commonly encountered in the south, was absent in the north; Peripartum Cardiac Failure (PPCF), rarely reported from the south, formed the commonest cause of cardiac failure among the females in the north. Rheumatic heart diseases (RHD) showed a uniform distribution throughout the country. Anaemia caused a higher percentage (13%) of cardiac failure in the north. Hypertension caused relatively fewer (12%) cardiac failures. The variations in the pattern of cardiac failure in these two areas of Nigeria are probably partly attributable to geographic geo-climatic, socio-economic, ethnic and cultural differences.